HF Advisory Group LLC Buys 441 Shares of Becton, Dickinson and Company (NYSE:BDX)

HF Advisory Group LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 12.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,885 shares of the medical instruments supplier’s stock after purchasing an additional 441 shares during the period. HF Advisory Group LLC’s holdings in Becton, Dickinson and Company were worth $937,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Ameriprise Financial Inc. increased its position in shares of Becton, Dickinson and Company by 6.4% during the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock valued at $1,181,483,000 after buying an additional 302,893 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Becton, Dickinson and Company by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock valued at $1,146,374,000 after purchasing an additional 87,230 shares during the period. Bank of New York Mellon Corp grew its position in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after purchasing an additional 346,720 shares in the last quarter. Clearbridge Investments LLC raised its position in shares of Becton, Dickinson and Company by 3.1% in the second quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock worth $697,513,000 after buying an additional 89,157 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after buying an additional 688,296 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of several recent analyst reports. Raymond James lowered their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Trading Up 1.3 %

BDX stock opened at $237.30 on Wednesday. The company has a market capitalization of $68.59 billion, a PE ratio of 48.83, a price-to-earnings-growth ratio of 1.76 and a beta of 0.43. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $259.92. The company’s 50 day moving average price is $237.51 and its two-hundred day moving average price is $235.12.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.